Drug Channels
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/

Drug Channels's articles

  1. Technology & Innovation

Three Technology Tactics for Overcoming Prior Authorization Hurdles

Today’s guest post comes from Karina Castagna, SVP of Access and Adherence at OptimizeRx. Karina discusses the challenges health care providers and patients face in their quest to secure prior authorizations from payers. She argues that manufacturers adopt an electronic health record-based solution to facilitate access to therapies, from the point of prescription through the […]
2 min read
0
  1. Media & Marketing

The Shady Business of Specialty Carve-Outs

Watch out! Plan sponsors are getting even bolder in their attempts to grab financial support intended for patients. The latest scam is called a specialty carve-out. Here’s the game: A commercial plan eliminates coverage for all specialty drugs. Beneficiaries are then shunted over to a charitable foundation, because they are now disguised as uninsured—at least […]
2 min read
0
  1. Trends & External Forces

Who Will Pay for Prescription Drugs in 2030? (Hint: It’s Us) (rerun)

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook . Note that the forecasts below did not account for policy changes that could further reduce pharmaceuticals’ share of U.S. healthcare spending. Click here to see the original post from April 2022. The econowonks […]
2 min read
0
  1. Data & Insights

Gross-to-Net Bubble Update: 2021 Pricing Realities at 10 Top Drugmakers (rerun)

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook . Click here to see the original post from May 2022. Time for Drug Channels’ annual update on pricing at the largest pharmaceutical manufacturers. This year’s review includes 10 companies: Eli Lilly […]
3 min read
0
  1. Data & Insights

DCI’s Top 15 Specialty Pharmacies of 2021—And Three Factors That Will Reshape 2022 (rerun)

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook . One update to the list below: CVS Health has quietly purchased AmerisourceBergen’s US Bioservices specialty pharmacy. Click here to see the original post from May 2022. In Drug Channels Institute’s list […]
2 min read
0
  1. Data & Insights

Warped Incentives Update: The Gross-to-Net Bubble Exceeded $200 Billion in 2021 (rerun)

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook . ICYMI, the unimplemented rule to reform rebates in Medicare Part D remains the ultimate budget gimmick. More than $122 billion in “savings” (offsets) from the current drug pricing reconciliation legislation comes from […]
3 min read
0
  1. Data & Insights

The Top Pharmacy Benefit Managers of 2021: The Big Get Even Bigger (rerun)

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Click here to see the original post from April 2022. The highly-consolidated PBM market notched another year of increased concentration. Consider Drug Channels Institute’s latest estimates of pharmacy benefit manager (PBM) market […]
2 min read
0
  1. Data & Insights

The New Hub Features Improving Patient Assistance

Today’s guest post comes from Ian Ocilka, Senior VP of Client Solutions at ConnectiveRx. Ian shares an overview of The Evolving Role of Hubs and Patient Services, his recent presentation at Informa Connect’s Hub and Specialty Model East conference in June. Click here to watch Ian’s full presentation. Read on for Ian’s insights. Read more […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, July 2022: CVS vs. NACDS, ICER Impact, Biosimilar Boom, Deductible Doubts, and Alto Pharmacy (and me)

Cut through the steamy summer haze with our refreshing selection of articles and insights. In this issue: CVS disassociates itself from its chain pharmacy association Payers are paying attention to ICER Benefits of the biosimilar boom A fantastic takedown of health insurance deductibles Plus, I join the Advisory Board of Alto Pharmacy. P.S. Join my […]
2 min read
0
  1. Data & Insights

What Manufacturers Need to Know About Alternative Payment Models

Today’s guest post comes from Carolyn Zele, Senior Manager of Solution Enablement at MMIT. Carolyn explains the advantages of alternative payment models (APM) for measuring and rewarding value and outcomes in our healthcare system. For more on how APMs measure value, click here to learn about MMIT’s Pulse Analytics Solution. Read on for Carolyn’s insights. […]
2 min read
0
  1. Department: HBC

Exclusive: Five Pharmacy Chains and PBMs Dominate 2022’s Still-Booming 340B Contract Pharmacy Market

Despite what you may have heard, pharmacy participation in the 340B Drug Pricing Program continues to thrive. Drug Channels Institute’s latest analysis reveals that an astonishing 32,000 pharmacy locations—more than half of the entire U.S. pharmacy industry—now act as contract pharmacies for the hospitals and other healthcare providers that participate in the 340B program. Over […]
2 min read
0
  1. Data & Insights

GoodRx Pharma Manufacturer Solutions: Partnering for Patient Access and Affordability

Today’s guest post comes from Akeel Williams, VP of Strategy and Operations, Pharma Manufacturer Solutions at GoodRx Akeel provides an overview of GoodRx’s Pharma Manufacturer Solutions business. He describes how GoodRx leverages its consumer reach to help biopharma companies boost awareness and utilization of manufacturers’ copay assistance programs. Click here to learn more about GoodRx’s […]
2 min read
0